ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

Trial Details

NCT ID

NCT06997081

Phase

PHASE2

Sponsor

University of Miami

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Lenalidomide
Dexamethasone
Elranatamab

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Newly diagnosed patients with histologically confirmed multiple myeloma (MM) based on the IMWG diagnostic criteria and measurable disease within th…
Serum monoclonal protein ≥ 1.0 g/dL
Urine monoclonal protein ≥ 200 mg/24 hour
Involved serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal kappa/lambda ratio

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →